Delivery Order SPE2DB22D9207-SPE2DB25FH5FC
- Not listed
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order by the Defense Logistics Agency (DLA) on August 27, 2025, for the supply of Jakafi 15 mg tablets (60-count units). This firm fixed-price delivery order, valued at $36,115.27, represents a single issuance under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA under the SPE2DB program, which carries a total value of $500...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order by the Defense Logistics Agency (DLA) on August 19, 2025, for the supply of Jakafi 10 mg tablets (60-count units). This firm fixed-price delivery order, valued at $12,115.65, is part of DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA under the SPE2DB program, which carries a total contract value of $499,999,999 through...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order on July 28, 2025, by the Defense Logistics Agency (DLA) for the supply of Jakafi 15 mg tablets (60 count). This $24.0K firm fixed-price delivery order, which was completed on July 29, 2025, carries no set-aside designation and represents a single transaction under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA. The...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, has been awarded a delivery order by the Defense Logistics Agency (DLA) for Jakafi 10 mg tablets (60-count units) with a ceiling value of $24,231.30. The contract, awarded on August 21, 2025, with an ultimate completion date of August 22, 2025, utilizes a firm fixed-price delivery order structure with no set-aside designation. This award is issued under DMS Pharmaceutical...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $12,089.78 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Jakafi 20 mg tablets (60-count units). The contract, awarded on August 25, 2025, with an ultimate completion date of August 26, 2025, utilizes firm fixed-price pricing with no set-aside designation. This delivery order falls under DMS Pharmaceutical Group's larger Indefinite...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $48,524.90 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Jakafi 5 mg tablets (quantity: 60s). The contract is firm fixed-price with no set-aside designation and an ultimate completion date of September 5, 2025. This delivery order is issued under DMS Pharmaceutical Group's existing single-award Indefinite Delivery Contract with the...
- The Defense Logistics Agency awarded a delivery order valued at $12,089.78 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Jakafi 20 mg tablets (60-count units). This firm fixed-price delivery order, issued on August 6, 2025, is due for completion by August 7, 2025, and carries no set-aside designation. DMS Pharmaceutical Group is performing under its larger Indefinite Delivery Contract with the DLA...
- The Defense Logistics Agency awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Jakafi 10 mg tablets (60-count units). This firm fixed-price delivery order, valued at $12,115.65, was awarded on July 22, 2025, with an ultimate completion date of July 23, 2025. The award carries no set-aside designation and represents a single delivery order issued under DMS Pharmaceutical Group's larger...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order on July 31, 2025, by the Defense Logistics Agency for the supply of Jakafi 10 mg tablets (60-count unit). This firm fixed-price delivery order, valued at $24,231.30, represents a single shipment under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA under the SPE2DB program. The contract includes no set-aside designation, and...
- The Defense Logistics Agency (DLA) awarded a $24,231.30 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Jakafi 10 mg tablets (60-count units). The award, issued on June 2, 2025, with an ultimate completion date of June 3, 2025, carries no set-aside designation. DMS Pharmaceutical Group will perform this delivery order from its Park Ridge, Illinois location, supplying the...
- SPE2DB22D9207Indefinite Delivery Contract
- SPE2DB22D9207-SPE2DB25FH5FCDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $86,098.80 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, on September 17, 2025. The delivery order is for Jakafi 15 mg tablets (60-count units) under a firm fixed-price contract type with an ultimate completion date of September 18, 2025. This award carries no set-aside designation and represents a direct delivery order issued against DMS Pharmaceutical Group's existing Indefinite Delivery Contract with the DLA under the SPE2DB program, a comprehensive pharmaceutical supply vehicle valued at $499,999,999 and valid through November 2026. DMS Pharmaceutical Group serves as a critical supplier within the federal pharmaceutical supply chain, providing prescription medications and medical supplies to Department of Defense healthcare facilities nationwide. Jakafi (ruxolitinib), a prescription medication used primarily for hematologic conditions, exemplifies the specialized pharmaceutical products the contractor distributes through the DLA's SPE2DB program. The company's established portfolio includes distribution of branded and generic prescription drugs, biologics, and medical consumables across multiple therapeutic categories, positioning it as a key distributor supporting military health facility operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $86.1k | 9/17/25 |